지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 저널정보
- 대한약학회 Archives of pharmacal research : a publication of the Pharmaceutical Society of Korea Archives of pharmacal research : a publication of the Pharmaceutical Society of Korea 제30권 제7호
- 발행연도
- 2007.1
- 수록면
- 898 - 904 (7page)
이용수
초록· 키워드
오류제보하기
1-Furan-2-yl-3-pyridine-2-yl-propenone (FPP-3) is an investigatory drug which has a dual inhibitory action on cyclooxygenase (COX) and 5-lipoxygenase (5-LOX). We examined its effect on the pharmacokinetics of warfarin. Three consecutive days of pretreatment with 17 mg/kg of FPP-3 had no significant effect on the pharmacokinetic parameters of warfarin when orally administered to rats. A higher dosage of FPP-3 however, did cause significant changes in the pharmacokinetic parameters of wafarin. The cytochrome P450 activity test demonstrated that the metabolism of R-warfarin was significantly inhibited by FPP-3 while there was little or no inhibition of the metabolism of S-warfarin, which is mainly responsible for its anticoagulant effect. Therefore, it appears that the alteration in the pharmacokinetic parameters of warfarin was due to the inhibitory effect of FPP-3 on the metabolism of R-warfarin. Although there was a significant increase in the plasma concentration, the area under the curve, half life of warfarin, and prothrombin time were not significantly changed. Based on these findings, the pharmacokinetic drug interaction between FPP-3 and warfarin mainly involves R-warfarin and, therefore, this interaction may not be of clinical significance in terms of warfarin-related toxicity.
목차
등록된 정보가 없습니다.
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Determination of Plasma Warfarin Concentrations in Korean Patients and Its Potential for Clinical Application
Annals of Laboratory Medicine
2009 .01
-
Hepatotoxic Effects of 1-Furan-2-yl-3-pyridin-2-yl-propenone, a New Anti-Inflammatory Agent, in Mice
Biomolecules & Therapeutics(구 응용약물학회지)
2009 .01
-
Immunotoxicological Investigation of 1-furan-2-yl-3-pyridin-2-yl-propenone in Female BALB/c Mice
Biomolecules & Therapeutics(구 응용약물학회지)
2009 .01
-
In vitro Characterization of the Enzymes Involved in the Metabolism of 1-furan-2-yl-3-pyridin-2-yl-propenone, an Anti-inflammatory Propenone Compound
Archives of pharmacal research : a publication of the Pharmaceutical Society of Korea
2008 .01
-
와파린과 상호작용하는 한약재에 대한 고찰
대한한방내과학회지
2012 .01
-
1-Furan-2-yl-3-pyridin-2-yl-propenone의 TNF-${\apha}$ 유도성 MCP-1과 IL-8의 발현 억제를 통한 장 상피세포 염증 억제효과
약학회지
2008 .01
-
와파린의 HPLC 분석법 및 한국인에서의 약동학적 특징
약학회지
2005 .01
-
항응고제 Warfarin 복용환자에서 발생한 위장관 합병증 : 공장벽 혈종 및 장중첩증
Annals of Surgical Treatment and Research
1998 .01
-
Identification of 1-Furan-2-yl-3-pyridin-2-yl-propenone, an Anti-inflammatory Agent, and Its Metabolites in Rat Liver Subcellular Fractions
Archives of pharmacal research : a publication of the Pharmaceutical Society of Korea
2006 .01
-
CYP2C9 Mutation Affecting the Individual Variability of Warfarin Dose Requirement
Annals of Rehabilitation Medicine
2012 .01
-
Antithrombotic Medication and the Risk of Vitreous Hemorrhage in Atrial Fibrillation: Korean National Health Insurance Service National Cohort
Yonsei Medical Journal
2019 .01
-
와파린의 약물동태학에 니모디핀의 영향
한국임상약학회지
2013 .01
-
A Case of Intolerance to Warfarin Dosing in an Intermediate Metabolizer of CYP2C9
Yonsei Medical Journal
2005 .01
-
Bleeding Complications and Analysis of Risk factors in Patients on Warfarin after Mechanical Heart Valve Replacement
대한약학회 학술대회
2001 .01
-
Genome-wide Approach vs Candidate Gene Approach in Personalizing Warfarin Therapy
대한임상약리학회 심포지움
2008 .01
-
Development and Comparison of Warfarin Dosing Algorithms in Stroke Patients
Yonsei Medical Journal
2016 .01
-
Effects of Amlodipine on the Pharmacokinetics of Warfarin after Oral and Intravenous Administration of Warfarin in Rats
Biomolecules & Therapeutics(구 응용약물학회지)
2011 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0